JP2017518316A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017518316A5 JP2017518316A5 JP2016571246A JP2016571246A JP2017518316A5 JP 2017518316 A5 JP2017518316 A5 JP 2017518316A5 JP 2016571246 A JP2016571246 A JP 2016571246A JP 2016571246 A JP2016571246 A JP 2016571246A JP 2017518316 A5 JP2017518316 A5 JP 2017518316A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- complement
- seq
- acid sequence
- amino acids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1410116.6 | 2014-06-06 | ||
| GBGB1410116.6A GB201410116D0 (en) | 2014-06-06 | 2014-06-06 | Method of treatment |
| PCT/EP2015/062742 WO2015185760A1 (en) | 2014-06-06 | 2015-06-08 | Ornithodoros moubata complement inhibitor for use in the treatment of complement-mediated diseases in patients with c5 polymorphism |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017518316A JP2017518316A (ja) | 2017-07-06 |
| JP2017518316A5 true JP2017518316A5 (enExample) | 2019-11-14 |
| JP7045133B2 JP7045133B2 (ja) | 2022-03-31 |
Family
ID=51266841
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016571246A Active JP7045133B2 (ja) | 2014-06-06 | 2015-06-08 | Ｃ５多型を有する患者における補体媒介性疾患の治療に使用するためのオルニトドロス・モウバタ（Ｏｒｎｉｔｈｏｄｏｒｏｓ ｍｏｕｂａｔａ）補体阻害剤 |
| JP2017563314A Expired - Fee Related JP6767396B2 (ja) | 2014-06-06 | 2015-12-09 | 急性移植片対宿主病の治療に使用するためのオルニトドロス・モウバタ補体阻害剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017563314A Expired - Fee Related JP6767396B2 (ja) | 2014-06-06 | 2015-12-09 | 急性移植片対宿主病の治療に使用するためのオルニトドロス・モウバタ補体阻害剤 |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11052129B2 (enExample) |
| EP (1) | EP3151851B1 (enExample) |
| JP (2) | JP7045133B2 (enExample) |
| KR (1) | KR102439717B1 (enExample) |
| CN (1) | CN106659767B (enExample) |
| AU (1) | AU2015270396B2 (enExample) |
| BR (1) | BR112016028446A2 (enExample) |
| CA (1) | CA2951175A1 (enExample) |
| DK (2) | DK3151851T3 (enExample) |
| ES (2) | ES2906630T3 (enExample) |
| GB (1) | GB201410116D0 (enExample) |
| IL (1) | IL249237B (enExample) |
| MX (1) | MX382757B (enExample) |
| PL (2) | PL3151851T3 (enExample) |
| RU (1) | RU2700932C2 (enExample) |
| WO (1) | WO2015185760A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201410116D0 (en) * | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| WO2016198133A1 (en) * | 2015-06-08 | 2016-12-15 | Volution Immuno Pharmaceuticals Sa | Ornithodoros moubata complement inhibitor for use in the treatment of acute graft versus host disease |
| GB201602802D0 (en) * | 2016-02-17 | 2016-03-30 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| JP2019521105A (ja) * | 2016-06-07 | 2019-07-25 | ノバルティス アーゲー | 補体ｃ５多型を有する患者を治療するための抗ｃ５抗体 |
| SE540754C2 (en) * | 2016-11-30 | 2018-10-30 | Ikea Supply Ag | Molding of fiber blanks into three-dimensional fiber block |
| JP7153669B2 (ja) * | 2017-04-21 | 2022-10-14 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 瘢痕性眼炎症障害の治療のためのコバーシン |
| DK3612208T5 (da) | 2017-04-21 | 2024-09-02 | Volution Immuno Pharmaceuticals Sa | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse |
| WO2019186084A1 (en) * | 2018-03-26 | 2019-10-03 | The University Of Liverpool | Anti-complement histones |
| WO2020053206A1 (en) * | 2018-09-10 | 2020-03-19 | Volution Immuno Pharmaceuticals Sa | Coversin for use in the treatment of rheumatic diseases |
| GB201905810D0 (en) * | 2019-04-25 | 2019-06-05 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| GB202218084D0 (en) | 2022-12-01 | 2023-01-18 | Volution Immuno Pharmaceuticals Sa | Fusion proteins |
| GB202408081D0 (en) | 2024-06-06 | 2024-07-24 | Volution Immuno Pharmaceuticals Sa | Methods of removing impurities |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050054033A9 (en) * | 1995-08-30 | 2005-03-10 | Human Genome Sciences, Inc. | Methods and compositions for treating and preventing infection using human interferon regulatory factor 3 |
| GB0312619D0 (en) * | 2003-06-02 | 2003-07-09 | Evolutec Ltd | Complement inhibitors |
| ATE427356T1 (de) | 2003-06-02 | 2009-04-15 | Varleigh Ltd | Komplementinhibitoren aus zecken |
| GB0518443D0 (en) | 2005-09-09 | 2005-10-19 | Evolutec Ltd | Method of treating myasthenia gravis |
| PL2061501T3 (pl) * | 2006-09-08 | 2016-01-29 | Volution Immuno Pharmaceuticals Sa | Sposób leczenia zaburzeń oddechowych |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| GB0802116D0 (en) | 2008-02-05 | 2008-03-12 | Natural Enviromental Res Counc | Treatment |
| GB0906779D0 (en) * | 2009-04-20 | 2009-06-03 | Natural Environment Res Council | Composition |
| JP5840623B2 (ja) | 2010-01-08 | 2016-01-06 | ヴォリューション イミュノ ファーマシューティカルズ エスエイ | 気道のウイルス感染症の治療に用いるｅｖ５７６ |
| TW201418707A (zh) * | 2012-09-21 | 2014-05-16 | Alexion Pharma Inc | 補體組分ｃ５拮抗劑之篩選分析 |
| GB201410116D0 (en) | 2014-06-06 | 2014-07-23 | Volution Immuno Pharmaceuticals Sa | Method of treatment |
| DK3612208T5 (da) | 2017-04-21 | 2024-09-02 | Volution Immuno Pharmaceuticals Sa | Coversin til behandlingen af autoimmune sygdomme med blisterdannelse |
-
2014
- 2014-06-06 GB GBGB1410116.6A patent/GB201410116D0/en not_active Ceased
-
2015
- 2015-06-08 AU AU2015270396A patent/AU2015270396B2/en not_active Ceased
- 2015-06-08 CA CA2951175A patent/CA2951175A1/en active Pending
- 2015-06-08 US US15/315,136 patent/US11052129B2/en active Active
- 2015-06-08 BR BR112016028446A patent/BR112016028446A2/pt active Search and Examination
- 2015-06-08 RU RU2016151179A patent/RU2700932C2/ru active
- 2015-06-08 KR KR1020167036998A patent/KR102439717B1/ko active Active
- 2015-06-08 PL PL15728491T patent/PL3151851T3/pl unknown
- 2015-06-08 EP EP15728491.0A patent/EP3151851B1/en active Active
- 2015-06-08 WO PCT/EP2015/062742 patent/WO2015185760A1/en not_active Ceased
- 2015-06-08 JP JP2016571246A patent/JP7045133B2/ja active Active
- 2015-06-08 ES ES15728491T patent/ES2906630T3/es active Active
- 2015-06-08 DK DK15728491.0T patent/DK3151851T3/da active
- 2015-06-08 MX MX2016016139A patent/MX382757B/es unknown
- 2015-06-08 CN CN201580040646.5A patent/CN106659767B/zh active Active
- 2015-12-09 JP JP2017563314A patent/JP6767396B2/ja not_active Expired - Fee Related
- 2015-12-09 ES ES15807907T patent/ES2906632T3/es active Active
- 2015-12-09 DK DK15807907.9T patent/DK3302519T3/da active
- 2015-12-09 PL PL15807907T patent/PL3302519T3/pl unknown
- 2015-12-09 US US15/577,906 patent/US20180193417A1/en not_active Abandoned
-
2016
- 2016-11-27 IL IL249237A patent/IL249237B/en active IP Right Grant
-
2021
- 2021-05-28 US US17/333,675 patent/US20210283221A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017518316A5 (enExample) | ||
| Ma et al. | Significance of complement system in ischemic stroke: a comprehensive review | |
| Herz et al. | Myeloid cells in the central nervous system | |
| Prinz et al. | Microglia: unique and common features with other tissue macrophages | |
| Drissi et al. | Understanding the genetic basis of congenital insensitivity to pain | |
| Korn et al. | T cell responses in the central nervous system | |
| Couillin et al. | STING signaling and sterile inflammation | |
| JP6931330B2 (ja) | Ｔｐｐ１配合物及びｃｌｎ２疾患を治療するための方法 | |
| JP2018516944A5 (enExample) | ||
| JP2018520646A5 (enExample) | ||
| ATE551350T1 (de) | Verfahren und reagenzien zur behandlung und diagnose von gefässerkrankungen und altersbedingter makuladegeneration | |
| US20240100081A1 (en) | Compositions and methods for treating age-related macular degeneration and geographic atrophy | |
| Parajuli et al. | Strategies for manipulating microglia to determine their role in the healthy and diseased brain | |
| Hagemann et al. | Homozygous Smpd1 deficiency aggravates brain ischemia/reperfusion injury by mechanisms involving polymorphonuclear neutrophils, whereas heterozygous Smpd1 deficiency protects against mild focal cerebral ischemia | |
| Suresh et al. | Modulation of microglia activation and Alzheimer's disease: CX3 chemokine ligand 1/CX3CR and P2X: 7: R signaling | |
| JP2019521105A5 (enExample) | ||
| US20210268126A1 (en) | Treating spinal cord injury (sci) and brain injury using gsx1 | |
| Claeys et al. | Epilepsy and migraine in a patient with Urbach–Wiethe disease | |
| Rus et al. | The complement system in central nervous system diseases | |
| US12241066B2 (en) | Gene therapy of the FAAH pseudogene | |
| CN110343171A (zh) | 周围神经的IgG刺激髓鞘再生 | |
| JP2010533660A5 (enExample) | ||
| Rajan et al. | Snake venom-derived peptides as prospective pharmacological tools: recent trends | |
| JP7594752B2 (ja) | ミエロペルオキシダーゼ（ｍｐｏ）発現を調節するための方法および組成物 | |
| JP2015522601A5 (enExample) |